Spending on prescription medicines in the United States will increase 4-7 percent through 2021, reaching $580 billion to $610 billion, according to a report released by QuintilesIMS Holdings.
Artificial intelligence generated plenty of chatter amongst the pharma marketing intelligentsia in 2018. Will 2019 be the year when the industry fully embraces it as more than just a tactic?
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
Leadership representing the 2018 Manny Award agency and network winners and finalists share their views on various healthcare industry trends and developments.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.
Current health systems built to evaluate and pay for traditional drugs are going to struggle with gene and other unusual therapies – but manufacturers can take steps before launch to define how manufacturers assess and value these new products.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
A recent study of DTC advertising appearing in the Journal of General Internal Medicine concluded that few broadcast ads are compliant with FDA’s guidelines. The reality, though, might not be so cut and dried.
As more innovative – yet even more expensive – therapies enter the U.S. market, brand marketers will have to find equally new and innovative ways to prove the value of their medicines to payers and patients, especially as insurance plans continue to put more of the cost burden on patients.
On Oct. 28, 2016, my mother, Joan Biamonte, died of complications from metastatic carcinoma of the lung. Despite having her original tumor characterized and going through a regimen of chemotherapy allegedly tailored to her tumor type, her cancer proliferated and spread into her liver and brain.
Teva Pharmaceutical Industries Ltd. launched an asthma inhaler that will be the first direct competition to GlaxoSmithKline’s best-selling Advair.
President Trump, hoping to take on the opioid epidemic sweeping parts of America, tapped U.S. Rep. Tom Marino to head up the Office of National Drug Control Policy.
As biologic medications administered through prefilled syringes continue to supplement and enter new therapeutic areas, more and more patients will need to embark on a learning curve that is possibly unlike any they have experienced prior.
GlaxoSmithKline’s new CEO Emma Walmsley won a short-term reprieve from the threat of generic Advair with a delay in U.S. approval for Mylan’s copy of the blockbuster lung inhaler.
Two U.S. lawmakers sent a letter to PTC Therapeutics Inc. seeking information about the drugmaker’s pricing strategy for its recently acquired muscle-wasting disorder drug.
Nearly all patients who completed at least eight weeks of hepatitis C treatment with Gilead’s Harvoni were cured of the disease, according to PBM Prime Therapeutics.
Congressional Republicans recrafted their Obamacare replacement bill in hopes of satisfying critics.
CytomX Therapeutics and Bristol-Myers Squibb are strengthening their relationship with the expansion of a 2014 collaboration agreement. The companies announced a plan to include up to eight additional targets, six in oncology and two in non-oncology areas, using CytomX’s proprietary Probody platform.